Sign In
Buy DMTK
$0.0940
+0 (+0%)
At Close: Oct 21, 2024
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both date
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses to Contact the Firm
05:00am, Friday, 15'th Dec 2023
LOS ANGELES, CA / ACCESSWIRE / December 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or
NEW YORK , Dec. 14, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3,
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 14'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced t
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DermTech, Inc. (DMTK)
11:00am, Thursday, 14'th Dec 2023
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves
If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos
DMTK Investors Have Opportunity to Lead DermTech, Inc. Securities Fraud Lawsuit
09:00am, Thursday, 14'th Dec 2023
BENSALEM, Pa. , Dec. 14, 2023 /PRNewswire/ -- Law Offices of Howard G.
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
04:00am, Thursday, 14'th Dec 2023
LOS ANGELES, CA / ACCESSWIRE / December 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or
SHAREHOLDER ALERT: Levi & Korsinsky Notifies DermTech, Inc.(DMTK) Investors of a Class Action Lawsuit and Upcoming Deadline
05:45am, Tuesday, 12'th Dec 2023
NEW YORK , Dec. 12, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK) of a class action securities lawsuit. CLASS DEFINITION:
DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript
10:58pm, Thursday, 03'rd Aug 2023
DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relations Bret Christensen - President & Chief Executive O
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
05:25am, Tuesday, 20'th Jun 2023
Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.
DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates
07:01pm, Thursday, 04'th May 2023
DermTech, Inc. (DMTK) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.01 per share a year ago.
DermTech to Present at March Investor Conferences
08:05am, Friday, 03'rd Mar 2023
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announ
DermTech, Inc. (DMTK) Q4 2022 Earnings Call Transcript
08:51pm, Thursday, 02'nd Mar 2023
DermTech, Inc. (NASDAQ:DMTK ) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Call
DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Thursday, 02'nd Mar 2023
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.12% and 19.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
